MedTrace Logo

Stimulation Therapy for Apnea: Reporting Thoughts

NCT04768543 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2022-08-10

No results posted yet for this study

Summary

Upper airway stimulation (UAS) via unilateral implantation of a phasic hypoglossal nerve stimulation device is a safe and effective alternative treatment for patients with moderate to severe obstructive sleep apnea (OSA) who are unwilling or unable to adhere to positive airway pressure (PAP) therapy. Although adherence to UAS is higher than to PAP, there remain patients who are not using UAS consistently. The aim of this project is to explore critical factors in the use of UAS by OSA patients using qualitative research methods (personal interviews). The proposed study will provide crucial information about patients' concerns regarding UAS use and suggestions for how to support new UAS recipients.

Conditions

Interventions

DEVICE

Upper airway stimulation (Inspire Medical Systems, Inc.)

phasic hypoglossal nerve stimulation device

Sponsors & Collaborators

  • Inspire Medical Systems, Inc.

    collaborator INDUSTRY

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Faith Luyster, PhD · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-02
Primary Completion
2021-05-01
Completion
2021-05-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04768543 on ClinicalTrials.gov